Doctor Warns Of Risks In Rush To Embrace A COVID-19 Treatment : Coronavirus Live Updates As researchers herald dexamethasone as a potential breakthrough treatment for critically ill patients, Dr. Kirsten Lyke says publicizing research that hasn't been rigorously vetted could erode trust.
NPR logo

Doctor Warns Of Risks In Rush To Embrace A COVID-19 Treatment

  • Download
  • <iframe src="https://www.npr.org/player/embed/880872562/881173407" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Doctor Warns Of Risks In Rush To Embrace A COVID-19 Treatment

Doctor Warns Of Risks In Rush To Embrace A COVID-19 Treatment

  • Download
  • <iframe src="https://www.npr.org/player/embed/880872562/881173407" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

SCOTT SIMON, HOST:

Is dexamethasone good news in the treatment of coronavirus or another exaggerated or false hope? Doctors in the U.K. say that dexamethasone, a low-cost steroid, reduced deaths in COVID-19 patients on ventilators. But the findings are preliminary and come just as we've seen several other prominent revisions in the advice that scientists have offered around the coronavirus.

Kirsten Lyke runs a coronavirus vaccine trial at the University of Maryland and joins us now. Thanks so much for being with us.

KIRSTEN LYKE: Thank you for asking, Scott.

SIMON: I gather this U.K. trial was led by a team at Oxford. They say using this steroid could save one life for every eight people on a ventilator. But as I don't have to tell you, Dr. Lyke, people want to hear, should I take it or not?

LYKE: You know, it's an easy answer to say yes or no, but these are very complex things that need to be unwound. This is a press release, so they're going to basically give us sort of the bottom line. But many of us would like to see the peer-review paper to understand how these people were randomized, who was not randomized - that's important to know - and, you know, a lot of other questions to give us a little bit more understanding as to the results.

SIMON: If we were living in a world without a pandemic, how long would it take to get the results you need to be really confident about how to use this drug?

LYKE: Yeah, interesting that you ask that question because this year, there was a groundbreaking publication that demonstrated if you start steroids early in the evolution of acute respiratory distress syndrome, or ARDS, that you can get some positive results. It took them seven years from...

SIMON: Yeah.

LYKE: ...Start to results. And so, you know, we're in unprecedented times, and people really want to get results out quickly. But at the same time, if things are released too early or there's harm that occurs from the intervention, that really erodes public trust.

SIMON: The researchers who led this trial, I gather, say that dexamethasone should immediately become standard care in patients with severe cases of COVID. It sounds like you're uncomfortable with that.

LYKE: Well, I - you know, I'm cautiously optimistic. This study - it was only people who were on oxygen or people that were ventilated...

SIMON: Yeah.

LYKE: ...That got the significant improvement. And people that were not on oxygen actually tended towards some harm.

SIMON: At the same time, Doctor, can you understand families who say, look; we have a loved one who is very sick, and we're willing to take that chance?

LYKE: Yeah, I can totally understand that. And that's not just the patients; that's also the doctors. And early on in this pandemic, everyone wanted to have an intervention. Everyone wanted to do something. Sometimes doing something feels better...

SIMON: Yeah.

LYKE: ...Than just sitting back and waiting. And I think that's why we got into trouble with hydroxychloroquine and the concomitant drug, azithromycin, which is an antibiotic. You know, the two together really, probably, had a harmful effect, particularly with the conduction of the electrical waves in the heart. So we'll be able to unravel this in retrospect, but I think we just need to be extremely cautious when we implement any new interventions. Dexamethasone is not a new intervention, so we do have a lot of background with dexamethasone. I think we just need to know when's the best time to treat our patients and not induce harm.

SIMON: I wonder if you can help us understand something, Dr. Lyke. Can you see why people get confused? At one point, we hear from the highest medical levels - I don't mean the White House - you know, the average person will not have to wear a mask, to just a few weeks later, everybody ought to wear a mask. Can you see how people begin to feel exasperated?

LYKE: Yeah, it's frustrating. It's frustrating from our side, too. This is a completely new virus which is unprecedented. And it's true. Typically, we say that using a mask doesn't necessarily protect you; it protects other people. And I think that's the consistent message. When we're telling people to wear masks, it's really useless if you're the only one wearing it in a crowd. It has to be the entire crowd. You know, there's a lot of individualism in the United States, but the pandemic and the virus don't really respect the individualism. And I think we need to really be stepping up as a group and protecting each other.

SIMON: Dr. Kirsten Lyke of the University of Maryland, thanks so much for being with us.

LYKE: Thank you, Scott.

(SOUNDBITE OF MUSIC)

Copyright © 2020 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.